The closing price of Amicus Therapeutics Inc (NASDAQ: FOLD) was $11.43 for the day, down -0.95% from the previous closing price of $11.54. In other words, the price has decreased by -$0.11 from its previous closing price. On the day, 1807456 shares were traded.
Ratios:
Our analysis of FOLD’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.52 and its Current Ratio is at 2.88. In the meantime, Its Debt-to-Equity ratio is 2.78 whereas as Long-Term Debt/Eq ratio is at 2.73.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Morgan Stanley on December 19, 2023, Upgraded its rating to Overweight and sets its target price to $20 from $15 previously.
On September 09, 2022, Morgan Stanley started tracking the stock assigning a Equal-Weight rating and target price of $14.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 05 ’24 when MCGLYNN MARGARET G sold 7,500 shares for $13.40 per share. The transaction valued at 100,500 led to the insider holds 59,289 shares of the business.
MCGLYNN MARGARET G sold 7,500 shares of FOLD for $99,675 on Mar 04 ’24. The Director now owns 59,289 shares after completing the transaction at $13.29 per share. On Mar 01 ’24, another insider, Crowley John F, who serves as the Executive Chairman of the company, sold 29,181 shares for $13.35 each. As a result, the insider received 389,543 and left with 573,478 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FOLD now has a Market Capitalization of 3.38B and an Enterprise Value of 3.54B. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.45 while its Price-to-Book (P/B) ratio in mrq is 20.95. Its current Enterprise Value per Revenue stands at 8.85 whereas that against EBITDA is -38.39.
Stock Price History:
Over the past 52 weeks, FOLD has reached a high of $14.57, while it has fallen to a 52-week low of $9.70. The 50-Day Moving Average of the stock is 12.68, while the 200-Day Moving Average is calculated to be 12.38.
Shares Statistics:
FOLD traded an average of 3.15M shares per day over the past three months and 3.28M shares per day over the past ten days. A total of 293.59M shares are outstanding, with a floating share count of 286.50M. Insiders hold about 3.01% of the company’s shares, while institutions hold 106.62% stake in the company. Shares short for FOLD as of Feb 29, 2024 were 30.91M with a Short Ratio of 9.81, compared to 24.4M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 10.47% and a Short% of Float of 10.51%.
Earnings Estimates
The firm’s stock currently is rated by 9 analysts. On average, analysts expect EPS of -$0.06 for the current quarter, with a high estimate of -$0.03 and a low estimate of -$0.08, while EPS last year was -$0.18. The consensus estimate for the next quarter is -$0.02, with high estimates of $0.01 and low estimates of -$0.04.
Analysts are recommending an EPS of between $0.18 and -$0.09 for the fiscal current year, implying an average EPS of $0. EPS for the following year is $0.4, with 9 analysts recommending between $0.62 and $0.17.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 10 analysts. It ranges from a high estimate of $115.04M to a low estimate of $107M. As of the current estimate, Amicus Therapeutics Inc’s year-ago sales were $83.08M, an estimated increase of 34.80% from the year-ago figure. For the next quarter, 10 analysts are estimating revenue of $125.77M, an increase of 33.10% less than the figure of $34.80% in the same quarter last year. There is a high estimate of $129.46M for the next quarter, whereas the lowest estimate is $122M.
A total of 11 analysts have provided revenue estimates for FOLD’s current fiscal year. The highest revenue estimate was $548.49M, while the lowest revenue estimate was $511M, resulting in an average revenue estimate of $531.19M. In the same quarter a year ago, actual revenue was $399.36M, up 33.00% from the average estimate. Based on 11 analysts’ estimates, the company’s revenue will be $682.06M in the next fiscal year. The high estimate is $798.27M and the low estimate is $618.98M. The average revenue growth estimate for next year is up 28.40% from the average revenue estimate for this year.
